"Attikon" University Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Koumarianou, Anna
ALTA-3, NCT03596866 / 2018-001957-29: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Checkmark Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).
Checkmark Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Recruiting
3
246
Europe, Canada, US, RoW
Brigatinib, Alunbrig, Alectinib, Alecensa
Takeda, ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.), Takeda Development Center Americas, Inc. (TDCA), Takeda Development Center Americas, inc. (TDCA), Takeda Development Center Americas,inc. (TDCA)
ALK+ Advanced NSCLC
04/23
05/24
Psyrri, Amanda
GEA, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Checkmark HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Recruiting
3
714
Europe, Canada, RoW
Zanidatamab, ZW25, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil, In situ hybridization (ISH)-based companion diagnostic assay, Immunohistochemistry (IHC)-based companion diagnostic assay
Zymeworks Inc., BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
06/24
07/25
ZEAL-1L, NCT04475939 / 2020-002202-20: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

Calendar Jan 2024 - Jun 2024: From ZEAL-1L trial in combination with Keytruda for stage 3 or 4 NSCLC
Checkmark JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Checkmark [VIRTUAL] First-line (1L Maintenance Therapy with Niraparib (nira + Pembrolizumab (pembro vs Placebo + Pembro in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC: Phase 3 ZEAL-1L Study
Checkmark [VIRTUAL] First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Checkmark Niraparib (Nira) + pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
Recruiting
3
650
Europe, US, RoW
Niraparib, Pembrolizumab, Placebo
GlaxoSmithKline
Lung Cancer, Non-Small Cell
08/24
10/24
NCT01969578 / 2013-000314-38: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Checkmark Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) express…
Checkmark Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant AR expressing salivary glands carcinomas (SGCs)
Checkmark Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expres…
Recruiting
2
152
Europe
bicalutamide + triptorelin, Cisplatin + Doxorubicin, Carboplatin + Paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for Research and Treatment of Cancer (EORTC), Bluefish Pharmaceuticals AB, Debiopharm Research & Manufacturing, Fonds Baillet Latour, AIRC, & Fondazione IRCCS Istituto Nazionale dei Tumori, RARECAREnet, Cancer Research UK, Fondazione IRCCS Istituto Nazionale dei Tumori, Debiopharm Research and Manufacturing, European Organisation for Research and Treatment o, Fondazione IRCCS IstitutoNazionale dei Tumori di M
Salivary Gland Cancer
06/22
06/22
CERPASS, NCT04050436: Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Calendar Jan 2023 - Mar 2023: Topline data from CERPASS trial in combination with RP1 for advanced CSCC
Checkmark Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
Checkmark A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).
Checkmark CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma
Checkmark [VIRTUAL] A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Recruiting
2
180
Europe, Canada, US, RoW
Cemiplimab, Libtayo, RP1, Genetically modified herpes simplex type 1 virus
Replimune Inc., Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
10/22
03/25
NCT04632173: Head and Neck cancERs International cOviD-19 collabOraTion

Checkmark [VIRTUAL] HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
Recruiting
N/A
750
Europe, RoW
non interventional study
Hellenic Cooperative Oncology Group, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, National Cancer Centre, Singapore, Emory University, University of Toronto, University of Birmingham, The University of Queensland
Head and Neck Cancer, Covid19
06/22
12/22
NCT04490564: A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, Metastatic NSCLC or Metastatic Melanoma

Recruiting
N/A
185
Europe
PD-L1 Kit
Pharmassist Ltd, University of Athens
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
12/20
12/21
NCT04480814: A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue Samples of Patients With Metastatic ER+/HER2- Breast Cancer

Recruiting
N/A
120
Europe
PIK3CA kit
Pharmassist Ltd, University of Athens
Breast Cancer
04/21
10/21

Download Options